The Keio Journal of Medicine

As technology and communication evolve rapidly in this digital age, scholarly publishing is also undergoing a makeover to match the diverse needs of researchers and clinicians. The BMJ has been at the forefront of innovating the presentation of research to increase its readabillty and usefulness. This article presents some of recent formats used for research communication at the BMJ.

抄録全体を表示

抄録を表示する抄録を非表示にする

Fecal microbiota transplantation (FMT) is a treatment to restore the normal microbial composition of the gut by introducing fecal microbiota obtained from a healthy donor into a diseased individual. There has been a growing interest in the use of FMT as a treatment of various diseases including Clostridium difficile infection (CDI), inflammatory bowel disease, and irritable bowel syndrome. Despite the increasing application of FMT, there are no standard protocols. Many aspects of FMT procedures vary regarding donor selection, preparation of fecal materials, recipient preparation, and route of administration. FMT is most successful in treating recurrent CDI. A randomized controlled trial reported a success rate of approximaetly 90%. Ulcerative colitis (UC) is a potentially good indication for FMT, although limited evidence is available on the use of FMT for the treatment of UC. Only several small case series have been reported, and the results in terms of efficacy are inconsistent. FMT can also be used to treat diseases other than gastrointestinal disorders in which the gut microbiota is disturbed, e.g., cardiovascular diseases, autoimmune diseases, and metabolic disorders. There remain many unanswered questions with regard to FMT, and more research is required in this field.

抄録全体を表示

PDF形式でダウンロード (901K)

J-STAGEへの登録はこちら（無料）